The alpha‑1 antitrypsin deficiency therapy market is expanding due to increasing use of intravenous augmentation therapy, gene therapy trials, and enhanced screening of at-risk populations for early intervention. https://www.datamintelligence.com/research-report/alpha-1-antitrypsin-deficiency-therapy-market